ES2310931T3 - Analogos de interferon alfa humano de baja toxicidad. - Google Patents

Analogos de interferon alfa humano de baja toxicidad. Download PDF

Info

Publication number
ES2310931T3
ES2310931T3 ES98952350T ES98952350T ES2310931T3 ES 2310931 T3 ES2310931 T3 ES 2310931T3 ES 98952350 T ES98952350 T ES 98952350T ES 98952350 T ES98952350 T ES 98952350T ES 2310931 T3 ES2310931 T3 ES 2310931T3
Authority
ES
Spain
Prior art keywords
baselineskip
ifn
analog
polypeptide
ifnα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98952350T
Other languages
English (en)
Spanish (es)
Inventor
Howard M. Johnson
Carol H. Pontzer
Lorelie H. Villarete
Jackeline Campos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Pepgen Corp
Original Assignee
University of Florida
Pepgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, Pepgen Corp filed Critical University of Florida
Application granted granted Critical
Publication of ES2310931T3 publication Critical patent/ES2310931T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES98952350T 1997-10-20 1998-10-20 Analogos de interferon alfa humano de baja toxicidad. Expired - Lifetime ES2310931T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US954395 1992-09-30
US08/954,395 US6204022B1 (en) 1996-04-12 1997-10-20 Low-toxicity human interferon-alpha analogs

Publications (1)

Publication Number Publication Date
ES2310931T3 true ES2310931T3 (es) 2009-01-16

Family

ID=25495373

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98952350T Expired - Lifetime ES2310931T3 (es) 1997-10-20 1998-10-20 Analogos de interferon alfa humano de baja toxicidad.

Country Status (13)

Country Link
US (1) US6204022B1 (https=)
EP (1) EP1025124B1 (https=)
JP (2) JP2001520238A (https=)
KR (2) KR100586625B1 (https=)
CN (1) CN1240717C (https=)
AT (1) ATE402957T1 (https=)
AU (1) AU744774B2 (https=)
CA (1) CA2308116C (https=)
DE (1) DE69839812D1 (https=)
DK (1) DK1025124T3 (https=)
ES (1) ES2310931T3 (https=)
TW (1) TW593336B (https=)
WO (1) WO1999020653A1 (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
AU781377B2 (en) * 1999-08-27 2005-05-19 University Of Florida Research Foundation, Inc. Materials and methods for inhibition of IgE production
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
IL155730A0 (en) * 2000-11-03 2003-11-23 Biomedicines Inc Method for short-term and long-term drug dosimetry
WO2002045737A2 (en) * 2000-12-07 2002-06-13 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
KR20040022244A (ko) 2001-08-12 2004-03-11 펩젠 코포레이션 하이브리드 인터페론/인터페론 타우 단백질, 조성물 및사용방법
CA2466228A1 (en) * 2001-11-09 2003-08-07 Biomedicines, Inc. Method for treating diseases with omega interferon
AU2003228267A1 (en) * 2002-03-05 2003-09-22 Board Of Regents, The University Of Texas System Methods of enhancing immune induction involving mda-7
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
US20040126360A1 (en) * 2002-10-09 2004-07-01 Manning Mark C. Oral formulations for proteins and polypeptides
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN102836420B (zh) * 2003-03-03 2014-03-12 得克萨斯州大学系统董事会 包含mda-7的组合物和方法
US20050003533A1 (en) 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
AU2006211960A1 (en) * 2005-02-08 2006-08-17 Board Of Regents, The University Of Texas System Compositions and methods involving MDA-7 for the treatment of cancer
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
RU2288474C1 (ru) * 2005-12-28 2006-11-27 Федеральное государственное учреждение науки "Московский научно-исследовательский институт эпидемиологии и микробиологии имени Г.Н. Габричевского Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" (ФГУН МНИИЭМ им. Г.Н. Габричевского Роспотребнадзора) Способ определения токсического действия оральной мукозальной интерферонотерапии
US20070243163A1 (en) * 2006-02-17 2007-10-18 Chih-Ping Liu Respiratory tract delivery of interferon-tau
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012177892A2 (en) * 2011-06-21 2012-12-27 University Of Florida Research Foundation, Inc. Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
CN112043685A (zh) * 2020-09-18 2020-12-08 深圳科兴药业有限公司 重组人干扰素α1b突变体吸入溶液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US4460574A (en) 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
US4507281A (en) 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
EP0146903A3 (en) 1983-12-19 1987-07-22 Schering Corporation Production of a vector encoding a novel hybrid interferon species
US4892743A (en) 1983-12-21 1990-01-09 Schering Corporation Novel hybrid interferon species
US4636383A (en) 1984-08-29 1987-01-13 Schering Corporation Interferon-cyclaradine combination
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
DE3607835A1 (de) 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
US4846782A (en) 1986-03-14 1989-07-11 Schering Corporation Treatment of cancer with interferon and radiotherapy
EP0240224A3 (en) 1986-03-31 1989-02-01 Interferon Sciences, Inc. An alpha interferon analogue
ZA878295B (en) 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
TW391983B (en) 1992-10-30 2000-06-01 Univ Florida Human interferon TAU, processes thereof and pharmaceutical uses thereof
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them

Also Published As

Publication number Publication date
DE69839812D1 (de) 2008-09-11
CA2308116A1 (en) 1999-04-29
EP1025124B1 (en) 2008-07-30
EP1025124A1 (en) 2000-08-09
JP2008247926A (ja) 2008-10-16
AU744774B2 (en) 2002-03-07
US6204022B1 (en) 2001-03-20
KR20060015701A (ko) 2006-02-17
ATE402957T1 (de) 2008-08-15
WO1999020653A1 (en) 1999-04-29
CN1276797A (zh) 2000-12-13
DK1025124T3 (da) 2008-10-06
KR100861007B1 (ko) 2008-09-30
TW593336B (en) 2004-06-21
KR20010031206A (ko) 2001-04-16
KR100586625B1 (ko) 2006-06-07
JP2001520238A (ja) 2001-10-30
CN1240717C (zh) 2006-02-08
CA2308116C (en) 2010-12-14
AU9807298A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
ES2310931T3 (es) Analogos de interferon alfa humano de baja toxicidad.
Villinger et al. Comparative sequence analysis of cytokine genes from human and nonhuman primates
ES2243990T3 (es) Composicion de interferon hibrido y procedimiento de uso.
ES2214551T3 (es) Terapia de infusion continua de citocinas a baja dosis.
ES2173953T5 (es) Uso del il-12 y antagonistas del il-12 para la fabricacion de una composicion farmaceutica para el tratamiento de enfermedades autoinmunes.
ES2210864T5 (es) Uso de un interferon de consenso para reducir los efectos secundarios del tratamiento con interferon en hepatitis virica.
EP2343081A1 (en) Interferon analogs
JP2001520238A5 (https=)
ES2205037T3 (es) Factor linfocitario quimioatractivo y sus utilizaciones.
Dianzani et al. The biological basis for clinical use of interferon
EP3348275A2 (en) Cytokines and neuroantigens for treatment of immune disorders
CA2843495A1 (en) Hcv immunotherapy
US20030147889A1 (en) Antagonist of th-1 immunerresponse inducing cytokine for the treatment of autoimmune diseases
WO1994001125A1 (en) Composition and method of treating hepatitis b
Oritani et al. Interferon-ζ/limitin: novel type I interferon that displays a narrow range of biological activity
JPS6191135A (ja) γ−インタフエロン（γ−ＩＦＮ）を含有するリユ−マチ症治療剤
TW200800247A (en) Method of treatment using interferon-τ
Smalley et al. Interferons: current status and future directions of this prototypic biological
US6231850B1 (en) Canine interleukin 12
Bajpai et al. Immunomodulating activity of analogs of noninflammatory fragment 163–171 of human interleukin-1β
WO2003095488A1 (es) Antagonista quimérico anth1
JP2000504026A (ja) ウイルス感染に対する宿主防御機構の刺激
ES2239814T3 (es) Metodo de movilizacion de celulas madre hematopoyeticas.
Foster Novel Interferons: Is there Life in the Old Dog Yet?
JPH03127740A (ja) 悪性腫瘍治療剤